


Quick Heal

Security Simplified




Earnings Presentation | Q1 FY24




Global cybersecurity market overview

Enterprise market to maintain 95%+ share, growing at 3x consumer market till 2025




Within enterprise market, product segment to gain significant share, outpacing the overall market by 5pp



While the long-term growth of the industry is positive, we have witnessed headwinds for last 6-9 months


Rapid digitization has enhanced need for greater cybersecurity investments

Indian Mobile data usage highest in the world*




* GB per month per user; excluding Wifi

Digital Transactions – INR Billion



Social Network Penetration - India



1.2Bn+
Internet users



1.1Bn+
Smartphone users



5x
Internet usage
(FY16 – FY23)



20x
Mobile data usage
(FY16 – FY23)



People enrolled in the world's largest unique digital identity program

1.32b



Users engaged in social media

639m



Application downloads in 2020

30b




Average cost to subscriber per GB wireless data

Rs.6.98

Company at a glance



Our Journey



30 years
of simplifying security

Consumer Business


Quick Heal
Security Simplified

SECURITE

- 30 years into simplifying security
- Market leadership with over 30% in the Indian market
- Robust Sales & Distribution network in India



Revenue (INR Crs)



Current Scenario:

- Market Headwinds in the short term: Sudden decrease in IT spending since H2FY22
- The trend is visible across the global software industry
- We have started addressing the degrowth in the consumer business and are expecting the signs of revival in subsequent quarters.


Our Approach:

- Focusing towards maintaining our market share in the period
- Drive consumer awareness in the geography in cybersecurity specific domain

- FY21 revenues included Rs. 30 crores of spillover revenues from FY20 due to Covid pandemic, hence FY22 numbers are not comparable to FY21
- Segmental revenues are regrouped basis end customers

The Growth Story: Enterprise Solutions

- Incubated the enterprise cybersecurity through internal accruals
- Growth story for QH in the years to come
- Enterprise solutions represent 95% of the cybersecurity market, which is growing at a CAGR of 11% while Quick Heal is growing at 21%



Current Business Momentum:

- Enterprise segment outperforming the market growth rates
- Focused on mid-market penetration starting this year
- New products have started to get inroads and generate revenue this quarter.
- Growth in International revenue on a YoY basis with high success in LATAM and Africa
- We are anticipating accelerated growth in the segment going forward





Q1 FY24 EARNINGS HIGHLIGHTS

Actual Sales
Jan 24 - 105M
Target Sales
Jan 26 - 65M



Q1-FY24 Earnings Highlights

REVENUE



Q1-FY24 Revenue at

₹ **51.4** crs

EBITDA

Q1-FY24 EBITDA at

₹ **(15.1)** crs

PAT



Q1-FY24 PAT at

₹ **(12.8)** crs

DILUTED EPS

Q1-FY24 EPS at

₹ **(2.4)**

CONSUMER REVENUE

Q1-FY24 Consumer revenue at


₹ **27.4*** crs

ENTERPRISE REVENUE

Q1-FY24 Enterprise # revenue at

₹ **26.5*** crs

Q1-FY24 Revenue split




■ Consumer
■ Enterprise #

* Based on gross revenues before adjusting for sales incentives

Enterprise segment is inclusive of government clients


Q1-FY24 Consolidated Performance Highlights (YoY)

Revenue (INR Crs)




- Enterprise business continues to grow sustainably
- The decline in revenues are primarily due to temporary headwinds in consumer business.
- We are witnessing early signs of revival

EBIDTA (INR Crs)



- EBITDA drop is primarily due to the reduction in revenues.
- As the gross margins >95%, the change in revenue flows through the bottomline
- We expect this to revive from subsequent quarters


PAT (INR Crs)



PAT is inline with the movement in EBITDA


Q1-FY24 Consolidated Performance Highlights (QoQ)

Revenue (INR Crs)




- Enterprise business continues to grow sustainably
- We are witnessing early signs of revival in consumer business.

EBIDTA (INR Crs)






- We expect EBITDA to revive from subsequent quarters

PAT (INR Crs)



PAT is inline with the movement in EBITDA

Working Capital Analysis



- Calculation of Days = [(Particular heading/ TTM Sales) X (365 days)]
- Receivables have been considered net of Incentive

Q1-FY24 Income Statement

PARTICULARS (INR Crs)	Standalone		Consolidated	
	Q1-FY23	Q1-FY24	Q1-FY23	Q1-FY24
Total Revenue	61.09	51.43	61.08	51.44
Direct Cost	1.88	1.22	1.88	1.22
Gross Profit	59.21	50.21	59.20	50.22
Gross Margin	96.92%	97.63%	96.92%	97.63%
Operating Cost				
Research and Development (R&D)	27.82	31.85	27.82	31.85
Sales and Marketing (S&M)	18.42	17.64	18.43	17.64
General Administration (G&A)	11.81	15.92	11.90	15.81
Total Expenditure	58.05	65.41	58.15	65.30
EBITDA	1.16	(15.20)	1.05	(15.08)
EBITDA Margin	1.90%	-29.55%	1.72%	-29.32%
Depreciation	3.95	2.93	3.95	2.93
EBIT	(2.79)	(18.13)	(2.90)	(18.01)
EBIT Margin	-4.57%	-35.25%	-4.75%	-35.01%
Other Income	3.19	4.73	3.20	4.73
Profit Before Tax (before exceptional item)	0.40	(13.40)	0.30	(13.28)
Exceptional items	-	-	-	-
Profit before Tax after exceptional items	0.40	(13.40)	0.30	(13.28)
Tax	0.10	(0.52)	0.12	(0.52)
Profit After Tax (PAT)	0.30	(12.88)	0.18	(12.76)
PAT Margin	0.49%	-25.04%	0.29%	-24.81%

NOTE: Certain figures have been re-grouped wherever necessary

Q1-FY24 Ratio analysis

In %	Standalone		Consolidated	
	Q1FY23	Q1-FY24	Q1-FY23	Q1-FY24
Expenses				
Direct Cost / Revenue	3.08%	2.37%	3.08%	2.37%
R&D / Revenue	45.54%	61.93%	45.55%	61.92%
S&M / Revenue	30.15%	34.30%	30.17%	34.29%
G&A / Revenue	19.33%	30.95%	19.48%	30.73%
Total Cost / Revenue	95.02%	127.18%	95.20%	126.94%
Margin				
Gross Margin	96.92%	97.63%	96.92%	97.63%
EBITDA	1.90%	-29.55%	1.72%	-29.32%
EBIT	-4.57%	-35.25%	-4.75%	-35.01%
PBT	0.65%	-26.05%	0.49%	-25.82%
PAT	0.49%	-25.04%	0.29%	-24.81%


Historical Annual Consolidated Income Statement

PARTICULARS (INR Crs)	FY21	FY22	FY23
Total Revenue	333.04	341.90	278.09
Direct Cost	13.70	13.84	10.31
Gross Profit	319.34	328.06	267.78
Gross Margins (%)	95.89%	95.95%	96.29%
Operating Cost			
Total Expenditure	177.90	221.20	265.90
EBITDA	141.44	106.86	1.88
EBITDA Margins (%)	42.47%	31.26%	0.68%
Depreciation	19.49	17.38	15.99
EBIT	121.95	89.48	(14.11)
EBIT Margins (%)	36.62%	26.17%	-5.07%
Other Income	24.16	19.20	22.13
Profit Before Tax (PBT)	146.11	108.68	8.02
Tax	39.16	25.49	1.62
Profit After Tax (PAT)	106.95	83.19	6.40
PAT Margins (%)	32.11%	24.33%	2.30%
Basic & Diluted EPS (INR)	16.65	13.94	1.14

NOTE: Certain figures have been re-grouped wherever necessary

Capital Market Data


Stock Market Performance (as on 30th June, 2023)



Price Data (as of 30th June, 2023)

Face Value	10.00
Market Price	159.70
52 Week H/L	225.30/127.35
Market Cap (INR Mn)	8,475.89
Equity Shares Outstanding (Mn)	53.07
1 Year Avg. Trading Volume ('000)	128.47
1 Year Avg. Net Turnover (Mn)	23.74

Shareholding Pattern (as on 30th June, 2023)



Disclaimer



Quick Heal Technologies Limited

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness, or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward-looking statements" based on the currently held beliefs and assumptions of the management of Quick Heal Technologies Limited, which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.

Forward-looking statements involve known and unknown risks, uncertainties, and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company or industry results to differ materially from the results, financial condition, performance, or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment, and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties, and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.

This presentation is for general information purposes only, without regard to any specific objectives, financial situations, or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration therefrom.

This presentation is confidential and may not be copied or disseminated, in whole or in part, and any manner.

Valorem Advisors Disclaimer:

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness, and reasonableness of the contents of this Presentation. This Presentation may not be all-inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.

For further details, please feel free to contact our Investor Relations Representatives:



Mr. Anuj Sonpal
Valorem Advisors
Email: quickheal@valoremadvisors.com
Tel: +91-22-4903 9500

Investor Relations Officer
Mr. Deepak Kumar
Deepak.Kumar01@quickheal.co.in

Compliance Officer
cs@quickheal.co.in
+91-20-66813232

CIN No: L72200MH1995PLC091408
www.quickheal.co.in



Thank You